{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:49:11Z","timestamp":1792586951685,"version":"4.5.0"},"reference-count":42,"publisher":"MyJove Corporation","issue":"232","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/70785","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:07:14Z","timestamp":1780787234000},"source":"Crossref","is-referenced-by-count":0,"title":["A Propensity Score-Matched Protocol: Terazosin Plus Finasteride For Benign Prostatic Hyperplasia – Sex Hormone And Urinary Control Effects"],"prefix":"10.3791","author":[{"given":"Yanlei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"554078","DOI":"10.3389\/fendo.2021.554078","type":"journal-article","article-title":"Endocrinology of the aging prostate: current concepts","volume":"12","author":"Cannarella","year":"2021","unstructured":"Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Lausanne). 2021;12:554078.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"15579883211036786","DOI":"10.1177\/15579883211036786","type":"journal-article","article-title":"Global, regional, and national incidence and years lived with disability for benign prostatic hyperplasia from 1990 to 2019","volume":"15","author":"Xu","year":"2021","unstructured":"Xu XF, et al. Global, regional, and national incidence and years lived with disability for benign prostatic hyperplasia from 1990 to 2019. Am J Mens Health. 2021;15(4):15579883211036786.","journal-title":"Am J Mens Health"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"23019","DOI":"10.34119\/bjhrv6n5-323","type":"journal-article","article-title":"Benign prostatic hyperplasia and the urinary tract repercussions","volume":"6","author":"De Laura Cajub\u00e1 Vieira","year":"2023","unstructured":"De Laura Cajub\u00e1 Vieira B, Silva RDM, De Maria Laura Nunes Machado B, Santana KCA. Benign prostatic hyperplasia and the urinary tract repercussions. Braz J Health Rev. 2023;6(5):23019-23028.","journal-title":"Braz J Health Rev"},{"key":"ref4","type":"journal-article","article-title":"Recent developments in diagnostic ultrasound for lower urinary tract function","author":"Tomonori","year":"2024","unstructured":"Tomonori M. Recent developments in diagnostic ultrasound for lower urinary tract function. J Med Ultrason. 2024. doi:10.1007\/s10396-024-01494-0.","journal-title":"J Med Ultrason"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.33024\/mnj.v7i1.16315","type":"journal-article","article-title":"Hubungan lower urinary tract symptoms (LUTS) dengan kualitas hidup pasien benigna prostatic hyperplasia (BPH)","volume":"7","author":"Ipnamelti","year":"2025","unstructured":"Ipnamelti I, Bayhakki B, Hasneli YN. Hubungan lower urinary tract symptoms (LUTS) dengan kualitas hidup pasien benigna prostatic hyperplasia (BPH). Malahayati Nurs J. 2025;7(1):222-236.","journal-title":"Malahayati Nurs J"},{"issue":"2","key":"ref6","first-page":"1","type":"journal-article","article-title":"\u03b11-adrenoceptor antagonists and 5\u03b1-reductase inhibitors for urinary tract symptoms in benign prostatic hyperplasia","volume":"16","author":"Jack","year":"2024","unstructured":"Jack D. \u03b11-adrenoceptor antagonists and 5\u03b1-reductase inhibitors for urinary tract symptoms in benign prostatic hyperplasia. J Paramed Pract. 2024;16(2):1-9.","journal-title":"J Paramed Pract"},{"key":"ref7","type":"journal-article","article-title":"Recommendation of \u03b11-adrenoceptor antagonist dose increase therapy (DIT) for men with lower urinary tract symptoms associated with benign prostatic hyperplasia","author":"Masaki","year":"2021","unstructured":"Masaki W, Satoshi Y, Hidehiro K, Hironori I. Recommendation of \u03b11-adrenoceptor antagonist dose increase therapy (DIT) for men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Pediatr Urol Case Rep. 2021. doi:10.14534\/j-pucr.2022.285.","journal-title":"Pediatr Urol Case Rep"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.54112\/bcsrj.v2024i1.749","type":"journal-article","article-title":"Comparison of efficacy of PDE5 inhibitors (sildenafil) versus alpha-blockers (tamsulosin) in treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia","volume":"2024","author":"Iu","year":"2024","unstructured":"Iu HAQ, et al. Comparison of efficacy of PDE5 inhibitors (sildenafil) versus alpha-blockers (tamsulosin) in treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. Biol Clin Sci Res J. 2024;2024(1):749.","journal-title":"Biol Clin Sci Res J"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41574-024-01047-y","type":"journal-article","article-title":"Inflammation and resolution in obesity","volume":"21","author":"Sot\u00e1k","year":"2025","unstructured":"Sot\u00e1k M, Clark M, Suur BE, B\u00f6rgeson E. Inflammation and resolution in obesity. Nat Rev Endocrinol. 2025;21(1):45-61.","journal-title":"Nat Rev Endocrinol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"106088","DOI":"10.1016\/j.jff.2024.106088","type":"journal-article","article-title":"Cucumis sativus (Curcubitaceae) inhibits prostate carcinoma cell growth and prevents the testosterone-induced benign prostatic hyperplasia in Wistar rat","volume":"114","author":"Yengwa","year":"2024","unstructured":"Yengwa BB, et al. Cucumis sativus (Curcubitaceae) inhibits prostate carcinoma cell growth and prevents the testosterone-induced benign prostatic hyperplasia in Wistar rat. J Funct Foods. 2024;114:106088.","journal-title":"J Funct Foods"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-024-00833-z","type":"journal-article","article-title":"Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (the PINNACLE study)","volume":"27","author":"Kaplan","year":"2024","unstructured":"Kaplan SA, Moss JL, Freedman SJ. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (the PINNACLE study). Prostate Cancer Prostatic Dis. 2024;27(3):531-536.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00120-020-01319-1","type":"journal-article","article-title":"Surgical treatment of benign prostatic obstruction (BPO) in patients under anticoagulation: a review of the bleeding risks of established techniques","volume":"59","author":"Deininger","year":"2020","unstructured":"Deininger S, et al. Surgical treatment of benign prostatic obstruction (BPO) in patients under anticoagulation: a review of the bleeding risks of established techniques. Urologe A. 2020;59(10):1187-1194.","journal-title":"Urologe A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3389\/fphar.2020.00763","type":"journal-article","article-title":"Effects of tamsulosin combined with solifenacin on lower urinary tract symptoms: evidence from a systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials","volume":"11","author":"Song","year":"2020","unstructured":"Song Y, Chen G, Huang P, Hu C, Liu X. Effects of tamsulosin combined with solifenacin on lower urinary tract symptoms: evidence from a systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. Front Pharmacol. 2020;11:763.","journal-title":"Front Pharmacol"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/jac5.1646","type":"journal-article","article-title":"Part II: interactive case: combination therapies in benign prostatic hyperplasia","volume":"5","author":"Barna","year":"2022","unstructured":"Barna M, Luigi B. Part II: interactive case: combination therapies in benign prostatic hyperplasia. JACCP J Am Coll Clin Pharm. 2022;5(6):649-653.","journal-title":"JACCP J Am Coll Clin Pharm"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41574-024-01057-w","type":"journal-article","article-title":"Polycystic ovary syndrome as a metabolic disease","volume":"21","author":"Helvaci","year":"2025","unstructured":"Helvaci N, Yildiz BO. Polycystic ovary syndrome as a metabolic disease. Nat Rev Endocrinol. 2025;21(4):230-244.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.63623\/w6ghj032","type":"journal-article","article-title":"Impacts of selected heavy metals and pesticides on sperm parameters among men being evaluated for fertility in a tertiary hospital in south-west Nigeria","volume":"1","author":"Oladosu","year":"2025","unstructured":"Oladosu WO, Oladosu AO, Alayo MA, Jimoh OS, Oyewo RA, Oladosu-Aderolu OA. Impacts of selected heavy metals and pesticides on sperm parameters among men being evaluated for fertility in a tertiary hospital in south-west Nigeria. Adv Mod Biomed. 2025;1(2):2-10.","journal-title":"Adv Mod Biomed"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/RD9.0000000000000054","type":"journal-article","article-title":"Association of symptomatic late-onset hypogonadism and lower urinary tract symptoms in aging males: a community-based study","volume":"7","author":"Liang","year":"2023","unstructured":"Liang GQ, et al. Association of symptomatic late-onset hypogonadism and lower urinary tract symptoms in aging males: a community-based study. Reprod Dev Med. 2023;7(3):129-134.","journal-title":"Reprod Dev Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"101685","DOI":"10.1016\/j.eclinm.2022.101685","type":"journal-article","article-title":"The placebo response rate and nocebo events in obesity pharmacological trials: a systematic review and meta-analysis","volume":"54","author":"Chin","year":"2022","unstructured":"Chin YH, et al. The placebo response rate and nocebo events in obesity pharmacological trials: a systematic review and meta-analysis. EClinicalMedicine. 2022;54:101685.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.62382\/jcbt.v2i1.32","type":"journal-article","article-title":"Therapeutic efficacy of platinum-based medicines combined with various nanoparticles in the treatment of colorectal cancer: a comprehensive review","volume":"2","author":"Meng","year":"2025","unstructured":"Meng X. Therapeutic efficacy of platinum-based medicines combined with various nanoparticles in the treatment of colorectal cancer: a comprehensive review. J Cancer Biomol Ther. 2025;2(1):57-72.","journal-title":"J Cancer Biomol Ther"},{"issue":"25","key":"ref20","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","type":"journal-article","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"Mcconnell","year":"2003","unstructured":"Mcconnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398.","journal-title":"N Engl J Med"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","type":"journal-article","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","unstructured":"Roehrborn CG, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131.","journal-title":"Eur Urol"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/aja202223","type":"journal-article","article-title":"Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older","volume":"25","author":"Shao","year":"2023","unstructured":"Shao WH, et al. Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older. Asian J Androl. 2023;25(1):132-136.","journal-title":"Asian J Androl"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0022-5347(05)00708-1","type":"journal-article","article-title":"Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo","volume":"175","author":"Crawford","year":"2006","unstructured":"Crawford ED, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422-1426.","journal-title":"J Urol"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","type":"journal-article","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150-161.","journal-title":"Pharm Stat"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","type":"journal-article","article-title":"The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia","volume":"5","author":"Kim","year":"2018","unstructured":"Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018;5(1):28-32.","journal-title":"Asian J Urol"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ca.24218","type":"journal-article","article-title":"Characterizing prostate zonal shape changes associated with 5\u03b1-reductase inhibitors using MRI","volume":"37","author":"Vatansever","year":"2024","unstructured":"Vatansever A, Yetemen M, \u00d6ngen G, Ocako\u011flu G, Co\u015fkun B. Characterizing prostate zonal shape changes associated with 5\u03b1-reductase inhibitors using MRI. Clin Anat. 2024;37(7):815-820.","journal-title":"Clin Anat"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"102626","DOI":"10.1016\/j.eclinm.2024.102626","type":"journal-article","article-title":"Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial","volume":"72","author":"Wang","year":"2024","unstructured":"Wang J, et al. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial. EClinicalMedicine. 2024;72:102626.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.37586\/2686-8636-4-2023-295-300","type":"journal-article","article-title":"Uroselective \u03b11A-adrenoceptor antagonist tamsulosin in treatment lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"16","author":"Krivoborodov","year":"2024","unstructured":"Krivoborodov GG, Efremov NS, Shirin DA, Gontar AA, Tkacheva ON. Uroselective \u03b11A-adrenoceptor antagonist tamsulosin in treatment lower urinary tract symptoms in men with benign prostatic hyperplasia. Russ J Geriatr Med. 2024;16(4):295-300.","journal-title":"Russ J Geriatr Med"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.14740\/jocmr5255","type":"journal-article","article-title":"Tamsulosin and dutasteride combination therapy for Asian men with moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review of clinical considerations that influence the prescription","volume":"16","author":"Yang","year":"2024","unstructured":"Yang F, Hashim R, Philippou J. Tamsulosin and dutasteride combination therapy for Asian men with moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review of clinical considerations that influence the prescription. J Clin Med Res. 2024;16(9):385-397.","journal-title":"J Clin Med Res"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000535606","type":"journal-article","article-title":"Comparison of monotherapies and combination therapy of tamsulosin and tadalafil for treating lower urinary tract symptoms caused by benign prostatic hyperplasia with or without erectile dysfunction: a meta-analysis","volume":"108","author":"Liu","year":"2024","unstructured":"Liu J, et al. Comparison of monotherapies and combination therapy of tamsulosin and tadalafil for treating lower urinary tract symptoms caused by benign prostatic hyperplasia with or without erectile dysfunction: a meta-analysis. Urol Int. 2024;108(2):89-99.","journal-title":"Urol Int"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e18761429315125","DOI":"10.2174\/0118761429315125240919033502","type":"journal-article","article-title":"Doxazosin attenuates development of testosterone propionate-induced prostate growth by regulating TGF-\u03b2\/Smad signaling pathway, prostate-specific antigen expression and reversing epithelial-mesenchymal transition in mice and stroma cells","volume":"17","author":"Li","year":"2024","unstructured":"Li Y, et al. Doxazosin attenuates development of testosterone propionate-induced prostate growth by regulating TGF-\u03b2\/Smad signaling pathway, prostate-specific antigen expression and reversing epithelial-mesenchymal transition in mice and stroma cells. Curr Mol Pharmacol. 2024;17:e18761429315125.","journal-title":"Curr Mol Pharmacol"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"e70085","DOI":"10.1111\/cid.70085","type":"journal-article","article-title":"Cortico-cancellous collagenic porcine bone for alveolar ridge preservation: a cohort comparative study","volume":"27","author":"Cinquini","year":"2025","unstructured":"Cinquini C, et al. Cortico-cancellous collagenic porcine bone for alveolar ridge preservation: a cohort comparative study. Clin Implant Dent Relat Res. 2025;27(4):e70085.","journal-title":"Clin Implant Dent Relat Res"},{"issue":"4","key":"ref33","first-page":"845","type":"journal-article","article-title":"Clinical outcomes of withdrawing one medication from long-term combination therapy comprising \u03b1-blocker and 5\u03b1-reductase inhibitor for benign prostatic hyperplasia","volume":"55","author":"Choi","year":"2023","unstructured":"Choi JD, Yoo TK, Kang JY, Jung HD, Lee JH. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising \u03b1-blocker and 5\u03b1-reductase inhibitor for benign prostatic hyperplasia. Int Urol Nephrol. 2023;55(4):845-851.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4081\/aiua.2022.4.521","type":"journal-article","article-title":"Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy","volume":"94","author":"Masuda","year":"2022","unstructured":"Masuda H, et al. Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy. Arch Ital Urol Androl. 2022;94(4):521-524.","journal-title":"Arch Ital Urol Androl"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2023.09.007","type":"journal-article","article-title":"Impact of relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study","volume":"84","author":"Tombal","year":"2023","unstructured":"Tombal B, et al. Impact of relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study. Eur Urol. 2023;84(6):579-587.","journal-title":"Eur Urol"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.63623\/9k14tf70","type":"journal-article","article-title":"Advances in combination therapy for gastric cancer: integrating targeted agents and immunotherapy","volume":"1","author":"Ren","year":"2024","unstructured":"Ren J. Advances in combination therapy for gastric cancer: integrating targeted agents and immunotherapy. Adv Clin Pharmacol Ther. 2024;1(1):1-15.","journal-title":"Adv Clin Pharmacol Ther"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"1557988320980180","DOI":"10.1177\/1557988320980180","type":"journal-article","article-title":"Efficacy and safety of combination comprising tamsulosin and PDE5-Is, relative to monotherapies, in treating lower urinary tract symptoms and erectile dysfunction associated with benign prostatic hyperplasia: a meta-analysis","volume":"14","author":"Sun","year":"2020","unstructured":"Sun K, et al. Efficacy and safety of combination comprising tamsulosin and PDE5-Is, relative to monotherapies, in treating lower urinary tract symptoms and erectile dysfunction associated with benign prostatic hyperplasia: a meta-analysis. Am J Mens Health. 2020;14(6):1557988320980180.","journal-title":"Am J Mens Health"},{"issue":"1","key":"ref38","type":"journal-article","article-title":"Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial","volume":"30","author":"Abbas","year":"2024","unstructured":"Abbas B, et al. Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial. Afr J Urol. 2024;30(1).","journal-title":"Afr J Urol"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12894-021-00941-1","type":"journal-article","article-title":"Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the national health insurance review and assessment service database","volume":"21","author":"Lulic","year":"2021","unstructured":"Lulic Z, et al. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the national health insurance review and assessment service database. BMC Urol. 2021;21(1):178.","journal-title":"BMC Urol"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.1007\/s10103-025-04478-9","type":"journal-article","article-title":"1470 nm diode laser enucleation versus bipolar transurethral resection of the prostate for the surgical management of benign prostatic hyperplasia: a randomized comparison","volume":"40","author":"Lin","year":"2025","unstructured":"Lin D, et al. 1470 nm diode laser enucleation versus bipolar transurethral resection of the prostate for the surgical management of benign prostatic hyperplasia: a randomized comparison. Lasers Med Sci. 2025;40.","journal-title":"Lasers Med Sci"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2023.02.028","type":"journal-article","article-title":"Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis","volume":"83","author":"Cornu","year":"2023","unstructured":"Cornu JN, et al. Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis. Eur Urol. 2023;83(6):534-547.","journal-title":"Eur Urol"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/med4.70030","type":"journal-article","article-title":"A bibliometric analysis of botulinum toxin type A in the treatment of lower urinary tract dysfunction: current research trends and perspectives","volume":"3","author":"Wang","year":"2025","unstructured":"Wang Z, et al. A bibliometric analysis of botulinum toxin type A in the treatment of lower urinary tract dysfunction: current research trends and perspectives. Med Adv. 2025;3(4):268-286.","journal-title":"Med Adv"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/70785\/a-propensity-score-matched-protocol-terazosin-plus-finasteride-for","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:33:20Z","timestamp":1792586000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/70785\/a-propensity-score-matched-protocol-terazosin-plus-finasteride-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":42,"journal-issue":{"issue":"232","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/70785","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}